Biostatistics LeadSanofi, San Diego, CA, USASan Diego, California, United States
PB0630 - Final Analysis of Long-term Clinical Outcomes of Prophylaxis With a Recombinant Factor VIII Fc Fusion Protein in Adults Aged ≥50 Years With Severe Hemophilia A
Monday, June 26, 202318:30 – 19:30 ET
PB0669 - Final Analysis of Long-term Clinical Outcomes of Recombinant Factor IX Fc Fusion Protein Prophylaxis in Adults ≥50 Years With Severe Hemophilia B
OC 65.1 - Long-Term Efficacy and Safety With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Immune Thrombocytopenia
Tuesday, June 27, 202314:45 – 15:00 ET
PB1458 - Thromboembolic (TE) Events in Cold Agglutinin Disease (CAD): Post-hoc Analysis PRE- and ON-sutimlimab Treatment in the Phase 3 CARDINAL and CADENZA Studies
Tuesday, June 27, 202318:30 – 19:30 ET
OC 69.5 - Outcomes in Adult and Adolescent Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis From an Observational Study With Factor VIII Prophylaxis
Wednesday, June 28, 202311:15 – 11:30 ET
